Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
about
The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series)Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series)Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophyCardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.Selective inhibition of class I but not class IIb histone deacetylases exerts cardiac protection from ischemia reperfusion.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Nuclear receptor corepressor complexes in cancer: mechanism, function and regulationComputational design of a time-dependent histone deacetylase 2 selective inhibitor.Autophagy as a therapeutic target in cardiovascular disease.Roles and post-translational regulation of cardiac class IIa histone deacetylase isoforms.Dynamic structure-based pharmacophore model development: a new and effective addition in the histone deacetylase 8 (HDAC8) inhibitor discovery.Non-sirtuin histone deacetylases in the control of cardiac agingHDAC inhibition attenuates cardiac hypertrophy by acetylation and deacetylation of target genes.Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.Integrating molecular genetics and systems approaches to pulmonary vascular diseases.Evidence for a non-canonical role of HDAC5 in regulation of the cardiac Ncx1 and Bnp genes.Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.Estrogen regulates histone deacetylases to prevent cardiac hypertrophy.Photoreactive "nanorulers" detect a novel conformation of full length HDAC3-SMRT complex in solutionIntroduction to the series: challenges and opportunities in pediatric heart failure and transplantation.Molecular mechanisms of diabetic cardiomyopathy.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionToward isozyme-selective inhibitors of histone deacetylase as therapeutic agents for the treatment of cancer.Natural products as zinc-dependent histone deacetylase inhibitors.Translational Perspective on Epigenetics in Cardiovascular Disease.Histone deacetylase inhibition reduces cardiac connexin43 expression and gap junction communication.Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.HDAC1 localizes to the mitochondria of cardiac myocytes and contributes to early cardiac reperfusion injury.New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death.A salt bridge turns off the foot-pocket in class-II HDACs.Epigenomes in Cardiovascular Disease.Obesity-mediated regulation of cardiac protein acetylation: parallel analysis of total and acetylated proteins via TMT-tagged mass spectrometryFood Bioactive HDAC Inhibitors in the Epigenetic Regulation of Heart FailureThe Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart
P2860
Q28069443-1C2EECA2-5EB5-4303-A769-3949BA84DD06Q28082797-07CE51CE-B304-4A26-ABD3-E3F05330470AQ28084598-26676E86-17A8-44C8-95AC-814588A3B511Q30618651-78762F3E-F2E6-4662-BCD4-38F4BEF3B863Q33714350-A2FF9963-63C3-4B2E-B68E-C7B23CCDA337Q33998649-C291DCA6-B663-42CB-9F9C-AD45F61DBDD0Q34448240-981A652E-42AA-43AD-B5FC-67B79C07FA3AQ35213063-BB402264-ECDE-4524-895D-D6DD12A421DEQ35223861-39C1D62E-8DEB-41AB-ACED-AAE79014F2CCQ35517710-72D11A53-F5D5-4985-9A63-C800D8C1F7A6Q35669576-98E5962C-9DA6-43EA-980F-E8C262CC7210Q35695849-BA6DBA9A-5F07-4CBF-8544-B7152A700F8DQ36212830-AD91ED63-8179-48C0-A3B4-D1415624D1B4Q36226378-B05366DB-DD7E-424D-A888-BA5CDF9EAF65Q36810797-2B494E75-C5AA-4CF2-8435-4D6307AF972FQ36870458-19D43B2A-A96E-44BD-95BE-2911B77E270DQ36932490-908AA3F5-F1D3-4F76-BA19-E35B3EE82C29Q37387804-0935356D-75AA-4A57-9877-045F6A0FE447Q37432970-F33F0F49-AD7E-43B0-A450-136AE7FB91AAQ37486302-8DDD1356-5EA9-4131-B993-0ECE84CEA3ABQ37672583-CEA36AD8-B94C-43E5-A52F-6E8B526F413DQ38105550-44AA15DB-C1AC-45A1-957A-40EEB2D237ADQ38155850-5486DA16-F3B0-4EDE-9171-73B8A1FA2568Q38315538-6D091DB3-BA42-48A8-B36A-7F8AC50873E0Q38650827-85D58731-CC08-48F2-9C15-7B4363FDEACCQ39830669-3CC2FE18-A2AE-46FF-A0A0-AAC8943EEB9AQ41178134-B323EF72-31B5-4A82-85E6-8FEDF542F294Q47390566-10366E6A-5C46-4C5F-BBD3-5BCD5016387AQ47682735-F5E3A97F-39E8-43A9-AFA8-127A1D5A2396Q48181021-4410232F-3EE7-4178-88B0-9C93A542F23EQ53060196-399C7FD6-355B-4847-83E3-8E2B93B4DFB2Q55098768-6CF7F2E1-E03D-4889-ABC0-1B37E3632A76Q58760378-50563604-E35C-4439-B2EF-CD8D7629D2D6Q58766782-63044B1E-E1EE-4916-9E6F-CE0F4881DE23Q60927794-bb2bc86c-475a-4ee4-16fa-1b23a5bad200
P2860
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@ast
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@en
type
label
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@ast
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@en
prefLabel
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@ast
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@en
P1476
Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
@en
P2093
Timothy A McKinsey
P304
P356
10.1016/J.YJMCC.2010.11.009
P577
2010-11-23T00:00:00Z